Yep, efficacy will definitely bring world-wide attention to this humble little stock that right now is quietly hidden away in the world's most remote city, and with it a MC that will be many, many multiples of where it sits currently.
Triple this you say Zac? I would suggest waaay beyond triple if efficacy is shown myself.
As the board of AGN put it, Proving the neuroprotective ability of ARG-007 will be a significant derisking milestone for the Company and opportunity to place Argenica at the forefront of neuroprotective clinical validation.
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007, page-16
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.0¢ |
Change
-0.015(2.26%) |
Mkt cap ! $79.83M | |||
| Open | High | Low | Value | Volume |
| 66.5¢ | 66.5¢ | 65.0¢ | $90.43K | 138.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6958 | 64.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 65.0¢ | 31813 | 1 |
View Market Depth
| Last trade - 15.46pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
66.0¢ |
Change
-0.015 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 65.5¢ | 66.5¢ | 65.0¢ | 58559 | ||
| Last updated 14.59pm 14/05/2024 ? | |||||
| AGN (ASX) Chart |